Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 5/20 | 0.53 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | CES1 | P23141 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ALPG | P10696 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7202862 | 0.96 | L3MBTL1 (0.55) | L3MBTL1TDP1LMNACES2CES1 | |
| SCHEMBL7200938 | 0.91 | TDP1 (0.50) | L3MBTL1TDP1LMNACES2CES1 | |
| SCHEMBL8992867 | 0.91 | L3MBTL1 (0.50) | L3MBTL1TDP1LMNACES2CES1 | |
| SCHEMBL7198527 | 0.88 | TDP1 (0.47) | L3MBTL1TDP1LMNACES2CES1 | |
| SCHEMBL7199609 | 0.88 | LMNA (0.60) | L3MBTL1TDP1LMNACES2CES1 | |
| SCHEMBL14519387 | 0.88 | L3MBTL1 (0.49) | L3MBTL1TDP1LMNACES2CES1 | |
| SCHEMBL838079 | 0.88 | L3MBTL1 (0.52) | L3MBTL1TDP1LMNACES2CES1 | |
| SCHEMBL19926126 | 0.88 | CES2 (0.47) | L3MBTL1TDP1LMNACES2CES1 | |
| SCHEMBL7198885 | 0.88 | CES2 (0.47) | L3MBTL1TDP1LMNACES2CES1 | |
| SCHEMBL7196088 | 0.84 | TSHR (0.47) | L3MBTL1TDP1LMNACES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115974721-B | Method for synthesizing 2-carbonyl substituted nitrile compound through 2, 2-trifluoroethyl ketone | 平顶山学院 | 2024-07-02 | — | — | CN | claimed |
| CN-113999232-B | MAT2A inhibitors | 南京正大天晴制药有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-115974721-B | Method for synthesizing 2-carbonyl substituted nitrile compound through 2, 2-trifluoroethyl ketone | 平顶山学院 | 2024-07-02 | — | — | CN | disclosed |
| US-RE49934-E1 | Inhibitors of cellular metabolic processes | SERVIER PHARMACEUTICALS LLC (US) | 2024-04-23 | — | — | US | disclosed |
| CN-109890822-B | Inhibitors of cellular metabolic processes | 安吉奥斯医药品有限公司 | 2022-08-30 | — | — | CN | disclosed |
| US-11325914-B1 | Inhibitors of cellular metabolic processes | SERVIER PHARMACEUTICALS LLC (US) | 2022-05-10 | — | — | US | disclosed |
| US-11325914-B1 | Inhibitors of cellular metabolic processes | SERVIER PHARMACEUTICALS LLC (US) | 2022-05-10 | — | — | US | disclosed |
| CN-113999232-A | MAT2A inhibitors | 南京正大天晴制药有限公司 | 2022-02-01 | — | — | CN | disclosed |
| US-10800782-B2 | Inhibitors of cellular metabolic processes | Agios Pharmaceutical, Inc. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10800782-B2 | Inhibitors of cellular metabolic processes | Agios Pharmaceutical, Inc. (US) | 2020-10-13 | — | — | US | disclosed |
| US-6908948-B1 | DNA-cleaving antitumor agents | RESEARCH DEVELOPMENT FOUNDATION (US) | 2005-06-21 | — | — | US | disclosed |
| US-6686345-B2 | INCLUDES AN AZA-ENEDIYNE, AZA-ENYNE ALLENE, OR AN AZA-DIALLENE; ARE PREFERABLY NON-HYDROLYZABLE, CATIONIC COMPOUNDS THAT BIND TO NUCLEIC ACIDS. | RESEARCH DEVELOPMENT FOUNDATION | 2004-02-03 | — | — | US | disclosed |
| WO-2003042148-A2 | PROCESS FOR PRODUCING BISBENZIL COMPOUNDS | SHOWA DENKO K. K. (JP) | 2003-05-22 | — | — | WO | disclosed |
| US-20020132797-A1 | DNA-cleaving antitumor agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-09-19 | — | — | US | disclosed |
| US-6297284-B1 | AZA-ENEDIYNE, AZA-ENYNE ALLENE, OR AN AZA-DIALLENE CATIONIC COMPOUNDS THAT BIND TO NUCLEIC ACIDS. | RESEARCH DEVELOPMENT FOUNDATION | 2001-10-02 | — | — | US | disclosed |
| WO-2001070217-A1 | DNA-CLEAVING ANTITUMOR AGENTS | RESEARCH DEVELOPMENT FOUNDATION (US) | 2001-09-27 | — | — | WO | disclosed |
| EP-1109552-A1 | NOVEL DNA-CLEAVING ANTITUMOR AGENTS | RESEARCH DEVELOPMENT FOUNDATION (US) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000003709-A9 | NOVEL DNA-CLEAVING ANTITUMOR AGENTS | UNIV TEXAS (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000003709-A1 | NOVEL DNA-CLEAVING ANTITUMOR AGENTS | RESEARCH DEVELOPMENT FOUNDATION (US) | 2000-01-27 | — | — | WO | disclosed |
| CN-1207390-A | Five-membered aromatic heterocyclic compounds contg. beta-position trifluoromethyl group and synthesis thereof | SHANGHAI INST ORGANIC CHEM (CN) | 1999-02-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800782-B2 | Inhibitors of cellular metabolic processes | MNAT1, MAT2A, PCK2 | L3MBTL1 2793/4885TDP1 1033/4885LMNA 2806/4885 |
| US-11325914-B1 | Inhibitors of cellular metabolic processes | MNAT1, MAT2A, PCK2 | L3MBTL1 2793/4885TDP1 1033/4885LMNA 2806/4885 |
| US-20020132797-A1 | DNA-cleaving antitumor agents | DNASE1, DNASE1L3, DCLRE1B | L3MBTL1 2894/4885TDP1 119/4885LMNA 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.